What are the geilines for adjusting basal insulin (long-acting insulin) in a patient with type 2 diabetes mellitus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Adjusting Basal Insulin in Type 2 Diabetes

Start basal insulin at 10 units once daily (or 0.1-0.2 units/kg), then increase by 2-4 units every 3 days based on fasting glucose until reaching 80-130 mg/dL, but stop escalating when the dose exceeds 0.5 units/kg/day and add prandial insulin instead. 1

Initial Dosing

  • Begin with 10 units once daily or 0.1-0.2 units/kg body weight administered at the same time each day (bedtime or with evening meal). 2
  • Continue metformin unless contraindicated, and possibly one additional non-insulin agent. 2, 1
  • For severe hyperglycemia (blood glucose ≥300-350 mg/dL or A1C ≥10-12% with symptoms), consider starting with 0.3-0.5 units/kg/day as basal-bolus therapy immediately rather than basal insulin alone. 2, 1

Systematic Titration Protocol

The titration schedule depends on fasting glucose levels:

  • If fasting glucose ≥180 mg/dL: Increase by 4 units every 3 days 1
  • If fasting glucose 140-179 mg/dL: Increase by 2 units every 3 days 1
  • Target fasting glucose: 80-130 mg/dL 1

Alternative approach: Increase by 10-15% of the current dose once or twice weekly until target is reached. 2, 1

  • Equip patients with self-titration algorithms based on self-monitoring of blood glucose—this improves glycemic control significantly. 2

Hypoglycemia Management During Titration

  • If hypoglycemia occurs without clear cause: Reduce dose by 10-20% immediately. 1
  • If >2 fasting glucose values per week are <80 mg/dL: Decrease basal insulin by 2 units. 1

Critical Threshold: When to Stop Escalating Basal Insulin

This is the most important clinical decision point to prevent "overbasalization":

  • When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, add prandial insulin rather than continuing to escalate basal insulin alone. 1

Clinical signals of overbasalization include: 1

  • Basal insulin dose >0.5 units/kg/day
  • Bedtime-to-morning glucose differential ≥50 mg/dL
  • Hypoglycemia episodes
  • High glucose variability

Adding Prandial Insulin (When Basal Insulin is Insufficient)

Add prandial insulin when: 1

  • Basal insulin is optimized (fasting glucose 80-130 mg/dL) but A1C remains above target after 3-6 months
  • Basal insulin dose approaches 0.5-1.0 units/kg/day without achieving A1C goal

Starting prandial insulin dose: 1

  • 4 units of rapid-acting insulin before the largest meal, OR
  • 10% of the current basal insulin dose per meal (if A1C <8%)

Titrate prandial insulin by 1-2 units or 10-15% every 3 days based on postprandial glucose readings. 1

Alternative to Prandial Insulin

  • Consider adding a GLP-1 receptor agonist to the basal insulin regimen to improve A1C while minimizing weight gain and hypoglycemia. 1
  • This combination provides potent glucose-lowering with less weight gain and hypoglycemia than intensified insulin regimens. 2, 1

Foundation Therapy Considerations

  • Continue metformin when initiating or intensifying insulin therapy—it reduces weight gain, lowers insulin requirements, and decreases hypoglycemia risk. 1, 3
  • Discontinue sulfonylureas, DPP-4 inhibitors, and GLP-1 receptor agonists once more complex insulin regimens beyond basal are used. 2
  • Consider adding SGLT2 inhibitors or pioglitazone in patients with suboptimal control requiring increasing insulin doses—these can improve control and reduce total insulin needed. 2

Monitoring Requirements

  • Daily fasting blood glucose monitoring is essential during titration. 1
  • Assess insulin dose adequacy at every clinical visit, looking for signs of overbasalization. 1
  • Check A1C every 3 months during intensive titration. 1

Common Pitfalls to Avoid

  • Do not delay insulin initiation in patients failing to achieve glycemic goals on oral medications—this prolongs hyperglycemia exposure and increases complication risk. 1, 3
  • Do not continue escalating basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia—this leads to overbasalization with suboptimal control and increased hypoglycemia risk. 1
  • Do not use insulin as a threat or describe it as punishment—explain the progressive nature of type 2 diabetes objectively. 2
  • Do not abruptly discontinue oral medications when starting insulin—continue metformin unless contraindicated. 1, 4

Patient Education Essentials

Comprehensive education must include: 2, 1

  • Blood glucose self-monitoring techniques
  • Hypoglycemia recognition and treatment (15 grams of fast-acting carbohydrate for glucose ≤70 mg/dL)
  • Proper insulin injection technique and site rotation
  • Nutrition management
  • "Sick day" management rules
  • Insulin storage and handling

Special Populations

Hospitalized patients (insulin-naive): 1

  • Start with 0.3-0.5 units/kg/day total daily dose
  • Give 50% as basal insulin and 50% as rapid-acting insulin before meals
  • Use lower doses (0.3 units/kg/day) for high-risk patients (elderly >65 years, renal failure, poor oral intake)

Patients on high-dose home insulin (≥0.6 units/kg/day): 1

  • Reduce total daily dose by 20% upon hospitalization to prevent hypoglycemia

References

Guideline

Insulin Therapy for Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Insulin Therapy Dosing and Regimen

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

EADSG Guidelines: Insulin Therapy in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.